You are here
Hemispherx to Present at the 8th Annual LD Micro Invitational
ORLANDO, Fla., May 10, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) announced today that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4 at 11:00 AM PT (the time may be subject to changes depending on the conference organizers) at the Luxe Sunset Boulevard Hotel in Bel Air, California. Hemispherx is a research and development company focused on unmet medical needs in immunology, with a special emphasis in immuno-oncology. It is also an emerging commercial development company, based upon commercial approvals of Alferon in the United States and Argentina for refractory or recurring external genital warts and Argentina for patients refractory to or intolerant to recombinant alpha interferon, as well as regulatory approval of Ampligen in Argentina for severe Chronic Fatigue Syndrome (CFS).
Thomas K. Equels, M.S. J.D., Chief Executive Officer of Hemispherx, will be presenting and meeting one-on-one with investors. Mr. Equels’ presentation will focus on immuno-oncology, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and immune system amplification for enhanced viral vaccines. Mr. Equels will discuss the completed production of a commercial size batch (~8,500 vials) of Ampligen for the company’s Early Access Programs for patients with Pancreatic Cancer and ME/CFS, as well as expanded clinical programs. Additional commercial size batches are planned for future commercial sales and clinical trials. The company projects an increase in revenues over the next twelve months of more than 300 percent compared to the preceding twelve months.
Hemispherx has two flagship products: Alferon N Injection®, approved in the United States and Argentina, and Ampligen®, approved in Argentina with an NDA pending in the United States. The company also has six orphan drug designations, with four in the United States and two in the European Union. Ampligen® has the potential to address multiple indications, including various cancers, ME/CFS and influenza. Alferon N Injection® also has multiple potential indications, including MERS and as a component of an immune modulating cocktail designed to favorably improve the microenvironment of several solid tumors. The potential combined market for these products is estimated to be in the billions.
View Hemispherx’s webcast here: http://wsw.com/webcast/ldmicro14/heb/
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. LD Micro are investors, first and foremost.
What started out as a newsletter highlighting unique companies has transformed into several influential conferences annually (Invitational, Summit, and Main Event).
In 2015, LD Micro launched ldmicro.com as a portal to provide exclusive intraday information on the entire sector, including the first pure microcap index (LDMi) which covers stocks in North America with market capitalizations between $50-$300m.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include the FDA approved drug Alferon N Injection® and the Argentina approved drug rintatolimod (tradenames Ampligen® or Rintamod®). Rintatolimod is a ribonucleic acid (RNA) being developed for globally important debilitating diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because rintatolimod has not been designated safe and effective by the FDA for general use, it is legally available in the United States only through clinical trials, however, Ampligen has been approved in Argentina for ME/CFS and the company is working toward legal access in other countries where early access programs exist for serious diseases such as ME/CFS where there are unmet medical needs. Ampligen is the only therapy approved anywhere in the world for ME/CFS. Also, an Ampligen EAP approval has been obtained for therapeutic use in the Netherlands for pancreatic cancer.
Cautionary Note Regarding Forward-Looking Statements
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
Hemispherx Biopharma, Inc.
Phone Number: 800-778-4042